Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): D ata from randomized controlled trials

Monami, Matteo, Nreu, Besmir, Scatena, Alessia, Cresci, Barbara, Andreozzi, Francesco, Sesti, Giorgio, Mannucci, Edoardo·2017·Diabetes, Obesity and Metabolism
DOI 10.1111/dom.12926

Cited by (241)

Items 201–241 of 241

  1. Making sense of newer treatment options for type 2 diabetes
    Phong Ching Lee, Matthew J. L. Hare, Leon A. Bach · 2018 · Internal Medicine Journal
  2. New advances and novel approaches in obesity pharmacotherapy
    Javier Gargallo Vaamonde, Gema Frühbeck, Javier Salvador · 2018 · Current Opinion in Endocrine and Metabolic Research
  3. Moderne Antidiabetika in der Kardiologie
    Christian Schneider, Roman Pfister · 2018 · Aktuelle Kardiologie
  4. The Effect of Glucagon-like Peptide-1 (GLP-1) on Obesity
    Xiaoyi Huang, Meihua Liang, Biyue Wei · 2019 · Critical Care Obstetrics and Gynecology
  5. The diabetes mellitus and oncopathоlogy
    Larysa Zhuravlyova, Неля Володимирівна Сокольникова · 2021 · Medicine of Ukraine
  6. Evidence-based use of newer agents in type 2 diabetes
    David Morris · 2021 · Journal of Prescribing Practice
  7. Metabolic syndrome and cancer risk
    Anirban Majumder, Shamasunder Acharya · 2024 · Elsevier eBooks
  8. Therapie des Typ-2-Diabetes
    R. Landgraf, M. Kellerer, E. Fach, B. Gallwitz, A. Hamann, H. Joost, H. Klein, D. Müller-Wieland, M. Nauck, H. Reuter et al. · 2013 · Diabetologie und Stoffwechsel
  9. Adjunctive Therapy, Including Pharmacotherapy
    Dalal Y. Al-Bazz, John P.H. Wilding · 2022 · Wiley eBooks
  10. GLP‐1 Receptor Agonists
    Catherine Russell and, John R. Petrie · 2022 · Wiley eBooks
  11. Management of type 2 diabetes without insulin: An update for the PCP
    Sudha Thiruvengadam, Patricia R. Peter · 2021 · Disease-a-Month
  12. Diabetes and cardiovascular outcome trials: a review with a focus on the use of glucagon-like peptide-1 receptor agonists in clinical practice
    Reyna Daya, Nasrin Goolam Mahyoodeen, Zaheer Bayat · 2021 · South African General Practitioner
  13. Therapie des Typ-2-Diabetes
    Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller‐Wieland, Michael Albrecht Nauck, Hans‐Martin Reuter, Erhard G. Siegel · 2021 · Der Diabetologe
  14. Liraglutide dans le traitement de l’obésité : une prise en charge multidisciplinaire
    Séverine Nest, Patricia Gilet, Véronique Di Vetta, Fanny Dudin, Johanna Frantz, Lucie Favre · 2022 · JMIG
  15. Hosszú hatású GLP-1-receptor-agonista szokatlan mellékhatása – a gastrointestinalis motilitás klinikai panaszokat okozó csökkenése IDegLira‑kezelés során – esetismertetés|
    Krisztina Arapovicsné Kiss, Lilla Borbáth, Péter Hajós, János Tibor Kis, Gábor Winkler · 2019 · Diabetologia Hungarica
  16. Therapeutic Proteins Used in Human Pancreatic Disease
    Ahamed Basha Abdul Bari, Prince Johnson Samuel · 2022 · Springer eBooks
  17. Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual
    Patricia R. Peter, Silvio E. Inzucchi · 2023 · Contemporary cardiology
  18. Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
    Shurui Hong · 2023 · BIO Web of Conferences
  19. Effekte einer Therapie mit Liraglutid bei Jugendlichen mit extremer Adipositas unter Real-Life-Bedingungen
    Melanie Schirmer, Stephanie Brandt, Stefanie Zorn, Martin Wabitsch · 2023 · Adipositas - Ursachen Folgeerkrankungen Therapie
  20. Glucagon-like peptide-1 receptor agonists : A new step towards weight management
    Mohamed Omar · 2023 · American Journal of Medical and Clinical Research & Reviews
  21. A very rare cause of markedly elevated CA 19–9: Glucagon-like peptide-1 receptor agonists
    Rongyue Liang, Zhifang Fu, Long Chen, Shuang Zhou, Hongmei Jiao · 2024 · Diabetes & Metabolism
  22. Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 study
    Xiaoling Cai, Linong Ji, Mingxia Yuan, Jianhua Ma, Fang Bian, Sheli Li, Wuyan Pang, Shuang Yan, Huimin Zhou, Minghui Hou et al. · 2024 · The Lancet Regional Health - Western Pacific
  23. Unraveling the safety and efficacy of semaglutide for people living with HIV and metabolic co-morbidities
    Dimitrios Patoulias, Paschalis Karakasis, Ieva Ruža, Mohamed El‐Tanani, Manfredi Rizzo · 2024 · Expert Opinion on Drug Safety
  24. Semaglutide: de la moda a la evidencia científica. A propósito de una Revisión Narrativa
    Elvio Bueno, Elías Jara-Ruiz, Jessica Jara, Maura Arce, Ana Iris Ramírez, Gabriela Canata · 2024 · Anales de la Facultad de Ciencias Médicas (Asunción)
  25. Glucagon-Like Peptide-1 Receptor Agonists
    Heather P. Whitley · 2025 · American Diabetes Association eBooks
  26. GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes
    David Morris · 2025 · Independent Nurse
  27. Association of GLP-1 receptor agonists with herpes risks in diabetes mellitus: a target trial emulation
    Chi-Hsien Huang, I-Hui Chiang, I-Cheng Lu, Po-Hsuan Lai, Pei‐Lun Liao, Huang Jing-yang, Ming-Ta Hsieh, Chi-Wei Lin, I-Ting Liu, James Cheng‐Chung Wei · 2025 · BMC Medicine
  28. Rôle des interactions mitochondrie-réticulum endoplasmique dans le contrôle de la sécrétion du Glucagon-Like Peptide 1 (GLP-1) et altérations au cours du diabète de type 2
    Alexandre Humbert · 2024 · theses.fr (ABES)
  29. Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge
    Sai Prasad, Aarushi Ahuja, Laxmansa C. Katwa, Shreya Sharma, Vidhi Parmar, Shaily Agrawal · 2026 · JCEM Case Reports
  30. Antidiabetic medications and the risk of bladder cancer in patients with diabetes mellitus: A systematic review and meta-analysis
    Dong Lei, Jin-H Wu, Xi-H Zeng, Ran Xu, Shun-S Zheng, Xue-J Zhu, Yang Jian-a · 2026 · Urologic Oncology Seminars and Original Investigations
  31. THE DARK SIDE OF GLP-1 ANALOGS: ADVERSE EFFECTS, LIMITATIONS, AND SAFETY CONCERNS
    Katarzyna Dudzińska, Adam Kaftan, Jan Plenikowski, Aleksander Kahsin, Sandra Kacprzak, Aleksandra Greluk, Jonasz Żuk, Wojciech Ciszewski, Alicja Jurewicz, Zofia Plenikowska · 2026 · International Journal of Innovative Technologies in Social Science
  32. Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists
    Claire B. Rosen, Denise W. Gee · 2026 · Advances in Surgery
  33. Sensitive issues of the incretin-based therapy
    I. BAKULIN, I. M. Sukhomlinova, YU Lebedeva, A. BELOUSOV · 2026 · Медицинский вестник МВД
  34. Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction
    Sandro La Vignera, Rosita Angela Condorelli · 2026 · Biomedicines
  35. Effects of Glucagon-Like Peptide-1 Receptor Agonists as Weight Loss Drugs on Pancreatitis and Pancreatic Cancer: A Meta-Analysis
    Xinai Zhong, Yueqi Zhao, Mengyao Han, Qiwen Zheng, Qianqian Cheng, Beixi Shi, Yu Zhang · 2026 · Hormone and Metabolic Research
  36. A retrospective cohort study on the comparative safety of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on the onset of gallbladder disease in type II diabetes
    Katie Carlson, Jasmeen Kaur, Charles E. Gaber, Sirimon Reutrakul, Kibum Kim · 2026 · Current Medical Research and Opinion
  37. Liraglutide
    Qing Zhong, Ashley L. Yang, Ines N Volic · 2026 · Elsevier eBooks
  38. Exenatide
    Qing Zhong, Ka Wai Wu, John Eri · 2026 · Elsevier eBooks
  39. Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
    Syed Arman Rabbani, Mohamed El-Tanani, Ismail Ibrahim Matalka, Manfredi Rizzo · 2026 · Frontiers in Endocrinology
  40. Suitability of the ICH S1B(R1) weight-of-evidence framework to evaluate glucagon-like protein-1 receptor agonist (GLP-1RA) carcinogenicity risk
    Katherine Adair Roach, Manoochehr Khazaee, Isaac Mohar, Denali Boon, Brigitte Cronin, Alex G. Gauthier · 2026 · Regulatory Toxicology and Pharmacology
  41. Therapie des Diabetes mellitus Typ 2
    Reiner Jumpertz von Schwartzenberg, Júlia Király · 2026 · Die Innere Medizin